Anavex Life Sciences Corp. · NASDAQ:AVXL
Anavex Life Sciences — Investor Presentation (November 2020)
29 slides from Anavex Life Sciences's investor presentation, November 2020

Slide 1: Corporate Presentation
Corporate Presentation Christopher U Missling, PhD | President & CEO Nasdaq: AVXL | November 2020

Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward-looking statements made within the meaning of the Private Securities Litigation Reform Act of 1995 by Anavex® Life Sciences Corp. and its representatives. These statements can be identified by introductory words such as “expects,” “plans,”

Slide 3: Broad Pipeline Targeting Neurodegenerative and Neurodevelopmental Diseases
Broad Pipeline Targeting Neurodegenerative and Neurodevelopmental Diseases with Significant Unmet Medical Need CANDIDATE PRECLINICAL PHASE 1 PHASE 2 PHASE 3 ALZHEIMER’S DISEASE AD ANAVEX®2-73-AD-004 ANAVEX®2-73 (Blarcamesine) PARKINSON’S DISEASE DEMENTIA ANAVEX®2-73-PDD-001 *RETT SYNDROME EXCELLENCE

Slide 4: Targeting Large Market Opportunities with Significant Unmet Medical Need
Targeting Large Market Opportunities with Significant Unmet Medical Need All U.S. Patient Numbers 1) Alzheimer’s Disease Facts and Figures. Alzheimers Dement 2018;14(3):367-429. 2) Marras C et al 2018. npj Parkinson's Disease volume 4, Article number: 21 3) Based on prevalence number on orphanet 4

Slide 5: Transformative Events for Anavex
Transformative Events for Anavex • Rett Syndrome Program Received Fast Track Designation and is Eligible for Pediatric Priority Review Voucher • Pursuing Large Markets with High Unmet Need by Applying Genetic Precision Medicine • Novel CNS Mechanism of Action Upstream of Neurodevelopment and Neurode

Slide 6: Catalysts to Drive Value
Catalysts to Drive Value The company has multiple near-term clinical milestones Full enrollment Phase 2 Parkinson’s disease dementia (PDD) Rett syndrome program received FDA Fast Track Designation and is eligible for FDA Pediatric Priority Review Voucher Initiate EXCELLENCE Phase 2/3 in pediatric Re

Slide 7: Clinical Trials – MoA and First Clinical Data
Clinical Trials – MoA and First Clinical Data: • Rett Syndrome (RTT) • Alzheimer’s Disease (AD) • Parkinson’s Disease Dementia (PDD)

Slide 8: ANAVEX 2-73 MoA: S1R Activation is Upstream from other Therapeutic Targets
ANAVEX®2-73 MoA: S1R Activation is Upstream from other Therapeutic Targets Neural cells suffer functional loss in neurological disorders which causes cellular stress Pathologies include: ü Aβ, Tau and ApoE fragmentation and dysfunction ü Proteinopathy ü Microglia activation, migration, and dysregula

Slide 9: ANAVEX 2-73 Establishes Human Proof-of-Concept and SIGMAR1 Target Occupancy
ANAVEX®2-73 Establishes Human Proof-of-Concept and SIGMAR1 Target Occupancy 2D [18F]FTC-146-PET imaging of ANAVEX®2-73: Dose- ANAVEX®2-73 positive response in functional dependent ANAVEX®2-73 Target Engagement (ADCS-ADL*) outcome in Alzheimer’s disease patients correlate with SIGMAR1 mRNA levels p-v

Slide 10: SIGMAR1 Activation has been Shown to Modulate Multiple Aspects of Neurodegenerative Processes
SIGMAR1 Activation has been Shown to Modulate Multiple Aspects of Neurodegenerative Processes Sigma-1 receptor agonists ANAVEX®2-73 enhances Sigma-1 receptor agonists have been shown to restore autophagy and alleviates Tau have a neuroprotective effect neuronal functions in pathology in neurodegener

Slide 11: What is Rett Syndrome?
What is Rett Syndrome? Devastating neuro-developmental disease in girls with both movement impairment and cognitive impairment Rett Syndrome (RTT) § Non-inherited genetic postnatal disorder caused by mutations in the MECP2 gene Ø Occurs almost exclusively in girls Ø Leads to severe impairments, affe

Slide 12: Phase 2 U.S. Rett Syndrome Part A: Improvement in All Key Domains
Phase 2 PART A: Improvement in All Key Domains U.S. Rett Syndrome ANAVEX®2-73-RS-001 Trial (NCT03758924) SUMMARY EFFICACY* • Phase 2, safety, tolerability, efficacy for 7 weeks, oral, liquid formulation, • Global severity RSBQ and CGI-I 5 mg daily (relatively low dose) RSBQ = Rett Syndrome Behavior

Slide 13: Precision Medicine
Precision Medicine Biomarkers Increase Probability of Success 76% 55% 46% 28% Phase II to Phase III Phase III to NDA/BLA Without Biomarkers With Patient Selection Biomarkers Thomas DW et al. Clinical Development Success Rates 2006-2015. BIO Industry Analysis 13

Slide 14: In patients with RTT, MeCP2 deficiency leads to increased glutamate
In patients with RTT, MeCP2 deficiency leads to increased levels of Glutamate, Loss of synaptic in comparison to homeostasis can healthy controls1,2,3, impair nerve cells which results in (neurons) and excitatory-inhibitory their connections imbalance and further synaptic dysfunction Glutamate as po

Slide 15: Part A: Reported Improvements Correlate with Biomarkers
Phase 2 PART A: Reported Improvements Correlate with Biomarkers U.S. Rett Syndrome ANAVEX®2-73-RS-001 Trial (NCT03758924) Glutamate REPORT on PART A: INTENSIVE PK SUBCOHORT Baseline We ek 7 0 • Plasma levels of the biomarker Glutamate decreased significantly (Week 0 vs. Week 7; 2-tailed Wilcoxon sig

Slide 16: ANAVEX 2-73 Phase 2 U.S. Rett Syndrome Study N=31
ANAVEX®2-73 Phase 2 U.S. Rett Syndrome Study N=31 * 7 RTT patient population ANAVEX®2-73 Primary and Secondary Endpoints Active dose# • PK, safety and tolerability of ANAVEX®2-73 • Diagnosis of • Behavioral symptoms confirmed RTT • Sleep function • Patients age >18 Randomization • Seizure activity •

Slide 17: ANAVEX 2-73 Phase 2 Rett Syndrome AVATAR Study N=33
ANAVEX®2-73 Phase 2 Rett Syndrome AVATAR Study N=33 * 7 RTT patient population ANAVEX®2-73 Primary and Secondary Endpoints Active dose# • Safety and tolerability of ANAVEX®2-73 • Diagnosis of • Behavioral symptoms confirmed RTT • Sleep function • Patients age >18 Randomization • Seizure activity • E

Slide 18: ANAVEX 2-73-RS-003 Rett Syndrome EXCELLENCE Study N>69
ANAVEX®2-73-RS-003 Rett Syndrome EXCELLENCE Study N>69 12 RTT patient population ANAVEX®2-73 Primary and Secondary Endpoints Active dose# • Safety and tolerability of ANAVEX®2-73 • Diagnosis of • Behavioral symptoms confirmed RTT • Sleep function • Patients age 5-18 Randomization • Seizure activity

Slide 19: Alzheimer's Disease (AD)
Alzheimer’s Disease (AD) Alzheimer’s disease is a progressive, irreversible neurological disease and the most common cause of dementia Alzheimer’s Disease (AD) § Alzheimer’s disease incidence highly correlates with age Ø AD prevalence in US:~5,700,000 Ø Estimated 50 million people live with dementia

Slide 20: Improved MMSE and ADCS-ADL Scores in Phase 2a AD Study through 148 Weeks
ANAVEX®2-73 Demonstrated Improved MMSE1 and ADCS-ADL2 Scores in Phase 2a AD Study through 148 Weeks Adjusted change in ADCS-ADL2 (±SE) Adjusted change in MMSE1 (±SE) N=8 N=8 N=13 N=13 p-value < 0.0008 p-value < 0.0001 Source: Hampel et al. A precision medicine framework using artificial intelligence

Slide 21: Phase 2b/3 Alzheimer's Disease and ATTENTION-AD OLE Study N=450
ANAVEX®2-73 Phase 2b/3 Alzheimer's Disease and ATTENTION-AD OLE Study N=450 48 … and Open Label Extension (OLE) 96weeks Primary Endpoints Early AD patient population • ADAS-Cog ANAVEX®2-73 • ADCS-ADL High dose# • Confirmed amyloid • Safety and tolerability of pathophysiology ANAVEX®2-73 (CSF/amyloid

Slide 22: Parkinson's Disease Dementia (PDD)
Parkinson’s Disease Dementia (PDD) Up to 80 percent of those with Parkinson’s disease eventually experience Parkinson’s disease dementia Parkinson’s Disease Dementia § Parkinson’s disease is a fairly common neurological disorder in older adults, estimated to affect nearly 2 percent of those older th

Slide 23: ANAVEX 2-73 PoC Phase 2 PDD Study Design
ANAVEX®2-73 PoC Phase 2 PDD Study Design A Phase 2 trial to Assess the Safety, Tolerability and Efficacy of ANAVEX®2-73 (blarcamesine) Oral Capsules in the Treatment of Parkinson’s Disease Dementia 1:1:1 randomization 2-week baseline period 3-week up-titration period 11-week target dose treatment pe

Slide 24: Key Cognitive Domains
Key Cognitive Domains Key cognitive features addressed by ANAVEX®2-73 (blarcamesine) The criteria from the National Institute on Aging and Alzheimer’s Association (NIA-AA) workgroup mention the following five Addressed in PoC cognitive domains when diagnosing MCI-AD: Phase 2 PDD Study (a) Episodic m

Slide 25: Significant Improvements in Episodic Memory with Increased Dose
Significant Improvements in Episodic Memory with Increased Dose ANAVEX®2-73-PDD-001 Study: Dose-dependent, statistically significant improvement of Quality of Episodic Memory with ANAVEX®2-73 (blarcamesine) Quality of Episodic Memory (counts) All participants Time: 14 weeks change from baseline • A

Slide 26: Summary of Topline Results
Summary of Topline Results: Broad and Significant Effects with ANAVEX®2-73 (blarcamesine) in PDD Patients • ANAVEX®2-73 (blarcamesine): a novel, oral, investigational sigma-1 receptor (Sig-1R / SIGMAR1) agonist with multimodal activity • Data confirm SIGMAR1 as gene “signature” biomarker of response

Slide 27: Anavex is pursuing Large Markets by Applying Precision Medicine
PRECISION MEDICINE IMPROVES CHANCE OF CLINICAL Anavex is pursuing Large Markets SUCCESS Testing for biomarkers demonstrated improved clinical response by Applying Precision Medicine to to ANAVEX ®2-73 in Rett syndrome correlated with glutamate and for Alzheimer’s and Parkinson’s patients carrying wi

Slide 28: Anavex Life Sciences Expertise
Anavex Life Sciences Expertise Management Team Christopher U. Missling PhD - President & CEO Walter E Kaufmann, MD - Chief Medical Officer Stephan Toutain, MS, MBA – Chief Operating Officer Emmanuel O Fadiran, RPh, PhD - SVP of Regulatory Affairs Daniel Klamer, PhD - VP of Business Development & Sci

Slide 29: Contact Us
Contact Us Corporate Office Anavex®Life Sciences Corp. 51 West 52nd Street, 7th floor New York, NY 10019 1-844-689-3939 Shareholder & Media Relations ir@anavex.com www.anavex.com NASDAQ: AVXL 29
Source: Internet Archive copy of anavex.com
More decks from Anavex Life Sciences Corp.
Proxy Contest (September 2026)25 slides · September 2026
AD/PD 2026, Copenhagen27 slides · Mar 21, 2026
Investor Presentation (February 2026)37 slides · February 2026
Investor Presentation (January 2026)37 slides · January 2026
Technical Presentation (February 2022)24 slides · Feb 2, 2022
Investor Presentation (September 2021)43 slides · Sep 13, 2021